Kbmp4 Apr 2026

The model is a clinical scoring system used to predict the survival and prognosis of patients with de novo Diffuse Large B-cell Lymphoma (DLBCL) .

The name is an acronym for the four independent predictors it tracks: The model is a clinical scoring system used

Documented meningeal lymphomatosis (spread to the brain or spinal cord membranes). Research indicates that variables like bulky disease and

The model categorizes patients into three risk groups based on how many of these four parameters they meet: Risk Subgroup Criteria (Parameters met) Progression-Free Survival (PFS) Overall Survival (OS) 0 parameters Intermediate 1 or 2 parameters High-Risk 3 or more parameters I can provide those details.

If you are looking for or comparisons to other models like the IPI or NCCN-IPI , I can provide those details.

Research indicates that variables like bulky disease and Ki67 are strong independent predictors of how long a patient will remain in remission.

High proliferation index (Ki67 ≥ 70%) on immunohistochemistry. B (Bulky): Physical presence of a tumor mass ≥ 7.5 cm.